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TGFαHigh levels of the S100 calcium binding protein S100A4 also called ﬁbroblast speciﬁc protein 1 (FSP1) have
been established as an inducer of metastasis and indicator of poor prognosis in breast cancer. The mechanism
bywhich S100A4 leads to increased cancer aggressiveness has yet to be established; moreover, the function of
this protein in normal mammary gland biology has not been investigated. To address the role of S100A4 in
normal mammary gland, its spatial and temporal expression patterns and possible function in branching
morphogenesis were investigated. We show that the protein is expressed mainly in cells of the stromal
compartment of adult humans, and during active ductal development, in pregnancy and in involution of
mouse mammary gland. In 3D culture models, topical addition of S100A4 induced a signiﬁcant increase in the
TGFα mediated branching phenotype and a concomitant increase in expression of a previously identiﬁed
branching morphogen, metalloproteinase-3 (MMP-3). These events were found to be dependent on MEK
activation. Downregulation of S100A4 using shRNA signiﬁcantly reduced TGFα induced branching and altered
E-cadherin localization. These ﬁndings provide evidence that S100A4 is developmentally regulated and that
it plays a functional role in mammary gland development, in concert with TGFα by activating MMP-3, and
increasing invasion into the fat pad during branching. We suggest that S100A4-mediated effects during
branching morphogenesis provide a plausible mechanism for how it may function in breast cancer
progression., Institute for Cancer Research,
y. Fax: +47 22871895.
Andersen).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
S100A4, also called FSP1, is a member of the S100 family of small,
calcium binding proteins. Since it was ﬁrst cloned from cultured rat
mammary myoepithelial cells (Barraclough et al., 1987), compelling
evidence links high expression of S100A4 to increased aggressiveness
of cancer cells. Experiments using transgenic animals (Ambartsumian
et al., 1996; Davies et al., 1996), overexpression (Davies et al., 1993)
and downregulation of S100A4 (Maelandsmo et al., 1996) have
conﬁrmed that the level of expression of this protein correlates with
metastasis. In a cohort of 349 early stage breast cancer biopsies, S100A4
expression was a stronger prognostic marker than both lymph node
inﬁltration and hormone receptor status (Rudland et al., 2000).
Additionally, S100A4 was one of only 25 genes found upregulated in
three different mammary cancer stem cell expression signatures(Gupta et al., 2009). Numerous other reports on clinical material from
breast (Ismail et al., 2008; Lee et al., 2004), bladder (Matsumoto et al.,
2007), colorectal (Flatmark et al., 2003; Gongoll et al., 2002), melanoma
(Andersen et al., 2004) and several other types of cancer (Garrett et al.,
2006) have conﬁrmed the association between S100A4 expression, and
a more severe prognosis. Collectively these ﬁndings suggest S100A4 as
a major determinant of breast cancer progression.
The members of the S100 protein family undergo conformational
changes during calcium binding, opening hydrophobic domains
responsible for binding target proteins. Even though several binding
partners have been suggested for S100A4, little is known about the
molecular function of this protein. S100 proteins are expressed both
intra-, and extracellularly, in a cell- and tissue-speciﬁcmanner (Donato,
2003), suggesting cell- and tissue-speciﬁc roles for the different family
members. S100A4 has been found in the nucleus, cytoplasm, and in the
extracellular microenvironment (Cabezon et al., 2007; Flatmark et al.,
2003), and in normal human tissues expression of the protein has
been reported in ﬁbroblasts (Strutz et al., 1995), endothelial cells
(Ambartsumian et al., 2001), hematopoietic cells (Cabezon et al., 2007;
Grigorian et al., 1994) and now in the mammary gland (this study).
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mechanism by which S100A4 exerts its metastasis-promoting effects
has not been elucidated. Since tumors essentially utilize tissue-
speciﬁc pathways and alter their regulations, we reasoned that we
may be able to decipher how the protein functions by investigating
its role in normal development. In this study, our goal was to
investigate the expression and biological function of the protein in
a normal and deﬁned organ as a comparison to the abnormal
situation during cancer onset and metastatic spread. Since S100A4
expression has the strongest impact in breast cancer, we analyzed
both mice and human mammary glands for expression and
regulation of S100A4 protein. In addition we used organotypic 3D
cultures of primary mouse mammary epithelial cells as well as non-
tumorigenic mammary epithelial cell lines from mice as functional
model systems.
The mammary gland undergoes extreme changes throughout
puberty, when the epithelial cells are triggered by a change in
hormonal status to proliferate and invade the mesenchyme. A highly
regulated process of branching morphogenesis ensues and gives rise
to a tree-like structure of ducts and secondary branches. An intricate
interplay between the epithelial cells and their microenvironmental
factors including hormones, growth factors, cytokines, proteases and
extracellular matrix (ECM) molecules, orchestrate the morphogenic
process (Fata et al., 2004; Nelson et al., 2006; Simian et al., 2001;
Sternlicht et al., 2006). Clearly the highly controlled branching
morphogenesis and the metastatic spread of carcinoma cells have a
number of similarities: both involve invasion into the surrounding
tissues and the ECM, increased proliferation and involvement of
metalloproteinases (MMPs).
An exploration of the expression of S100A4 in normal mammary
tissue revealed that S100A4 was expressed mainly in stromal cells
of the mammary gland, and its expression peaked during the period
of ductal elongation. Using three-dimensional (3D) organotypic
culture models, we demonstrated that S100A4 contributes to the
branching phenotype in normal epithelial cells through upregulation
of MMP-3 and through modulation of E-cadherin distribution.
Furthermore, we propose that tumor cells usurp the stromal role
of S100A4 on branching morphogenesis and use the pathway to
promote a metastatic phenotype.Materials and methods
Immunohistochemistry
Formalin-ﬁxed parafﬁn-embedded normal breast tissue were from
Abcam (Cambridge, MA). Before deparafﬁnizing, the sections were
baked for 45 min at 60 °C. The sections were immunostained using the
biotin–streptavidin–peroxidase method (Vector Laboratories, Burlin-
game, CA). Deparafﬁnized sections were microwaved in 1 mM EDTA
(pH8.0) for 10 min at 800W to unmask epitopes. After incubationwith
1% hydrogen peroxide for 10 min, the sections were blocked with 1.5%
normal horse serum in PBS for 30 min at ambient temperature, then
incubated with mouse monoclonal anti-human S100A4 antibodies
(22.3) (Flatmark et al., 2004), diluted 1:300, or, for the mouse sections,
anti-S100A4 rabbit polyclonal antibody (Dako, Copenhagen, Denmark)
diluted 1:300, in 1% BSA in PBS at 4 °C overnight. The sections were
thereafter incubated with biotin-labeled secondary antibody (1:200 in
PBSwith 1%BSA) and strepatvidin–peroxidase (1:30) both for 30 min at
ambient temperature. The sections were then stained with freshly
prepared 0.05% 3,3′-diaminobenzidine tetrahydrocloride containing
hydrogen peroxide, counterstained with hematoxylin, dehydrated and
mounted. The speciﬁcity of the S100A4 antibody is described elsewhere
(Flatmark et al., 2004). Negative controlswere obtained by replacement
of the primary antibody with mouse IgG of the same subclass and
concentration.Brightﬁeld microscopy
All images were acquired using a Zeiss Axiovert200M microscope
equipped with a Zeiss AxioCam color camera.
EpH4 cell culture
EpH4 cells were originally isolated from the mammary tissue of a
mid-pregnant Balb/c mouse (Reichmann et al., 1989) and were a gift
from E. Reichmann (Institut Suisse de Recherches, Epalinges,
Switzerland). Cells were maintained in 1:1 DMEM/F12 (University
of California San Francisco Cell Culture Facility), supplemented with
2% fetal bovine serum (Invitrogen, Carlsbad, CA), 50 μg/ml gentamy-
cin, and 5 μg/ml insulin (Sigma-Aldrich). The EpH4 cells were used
between passage 14 and 25. All shRNA transduced cell lines were used
between passage 3 and 10 after infection.
Isolation of primary mammary organoids
The primary mammary organoids were isolated as described in
Fata et al. (2007). In brief, the 4th inguinal mammary glands were
removed from 10- to 14-week-old virgin Balb/c mice and minced
(Animal protocol, #0522 at Lawrence Berkeley Labs approved by
the Animal Welfare and Research Committee (AWRC)). Minced tissue
(4–8 glands) was shaken for 30 min at 37 °C in a 50-ml collagenase/
trypsin mixture (0.2% trypsin (Sigma, St. Louis, MO), 0.2% collagenase
type IV (Gibco, Invitrogen), 5% fetal calf serum, 5 μg/ml insulin, 50 μg/
ml gentamycin, in 50 ml of DMEM/F12). The collagenase solution was
discarded after centrifugation at 1000 rpm, and the pellet was
resuspended in 10 ml DMEM/F12. The suspension was pelleted
again at 1000 rpm for 10 min, resuspended in 4 ml of DMEM/F12+
40 μl of DNase (2 U/μl), and incubated for 5 min at ambient
temperature. The DNase solution was discarded and the epithelial
pieces were separated from the single cells through differential
centrifugation performed at least 4 times. The ﬁnal pellet was
resuspended in the desired amount of medium or Matrigel (Growth
Factor Reduced Matrigel®, BD Biosciences, San Jose, CA).
Morphogenesis assays
Matrigel assay
Morphogenesis assays were performed as described in Fata et al.
(2007). In brief, the desired amount of primary organoids wasmixed in
Matrigel and added to a 96-well containing an underlay of 50 μl
solidiﬁedMatrigel. 150 μl of basalmediawas added to all wells (DMEM/
F12 with 1% insulin, transferrin, selenium, and 1% penicillin/streptomy-
cin) for 24 h.After 24 h, themediawas replenished (untreated samples)
and growth factor, TGFα (9 nM; Sigma, Saint Louis, MO), and
recombinant S100A4 (4 μg/ml or 20 μg/ml for all Matrigel cultures)
were added to basal media. Every other day, mediumof all sampleswas
replenished.
Collagen assay
For 3D cell cultures in 3 mg/ml collagen, primary organoids or
EpH4 cell clusters were embedded in type I collagen gels as previously
described (Hirai et al., 1998). In brief, the EpH4 cells were pre-
clustered in ultra low adhesion plates (Costar, Corning Life Sciences,
Lowell, MA, USA) for 24 h, and then collected by differential
centrifugation. Acid-soluble collagen (600 μl of a 5 mg/ml solution),
CellagenTM (AC-5, ICN, Koken, Tokyo, Japan) was mixed gently on ice
with 75 μl 10× DMEM/F12, followed by 75 μl of 0.1 N NaOH. The
cell clusters or organoids were suspended in DMEM/F12 at a
concentration of 2500–3000 clusters per ml, and 250 μl of the
suspension (or medium without clusters) was mixed with the ice-
cold collagen solution. Two layers of collagen were poured into each
well: a basal layer consisting only of collagen and an upper layer
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collagen layer, 50 μl of the collagen solutionwas poured into eachwell
of a 48-well dish and incubated at 37 °C for 15 min. Subsequently,
150 μl of the 3 mg/ml cluster containing collagen suspension was
poured onto the gelled basal collagen layer, and placed immediately at
37 °C. After gelation, 300 μl of chemically deﬁned medium consisting
of DMEM/F12 containing ITS (insulin/transferrin/selenium, Sigma)
with 9 nM TGFα alone or in combination with 12 μg/ml recombinant
S100A4 protein (rS100A4) was added. Recombinant S100A4 protein
was produced and puriﬁed as previously described (Pedersen et al.,
2004). As control, recombinant pro-gastrin releasing peptide (pro-
GRP), a kind gift from Dr. David Warren (Central Laboratory, Oslo
University Hospital, Radiumhospitalet, Oslo, Norway), or PBS, as
vehicle control, was used. Medium was replenished every 2–3 days.
Analysis of branching morphogenesis
The branching phenotype of organoids embedded in Matrigel was
determined after cultivation for 4–6 days, while EpH4 clusters
embedded in collagen was evaluated after 72 h. A branching
phenotype was deﬁned as an organoid or EpH4 cell cluster having
at least two processes (branches) extending from its central body.
Quantiﬁcation of EpH4 cell branching was carried out by counting the
percentage of branching clusters in each well. To determine the
morphogenic response of the primary organoids, all buds on the 10
largest organoids within each well (100–200 organoids/well) were
counted. All experiments were carried out in at least duplicates, and
repeated at least four times. Statistical signiﬁcance was determined
with two tailed Student's t-test. All error bars represent standard error
of the mean (SEM), if not stated otherwise.
Real-time reverse trancriptase PCR (qPCR)
Total RNA was isolated with QIAGEN RNeasy Mini Kit (Quiagen,
Valencia, CA). For cDNA synthesis, 10 ng of total cellular RNAwas used
to synthesize cDNA using SuperScript III First-Strand Synthesis
System (Invitrogen, Carlsbad, CA). S100A4 was ampliﬁed using the
following forward and reverse primers GAGCTCAAGGAGCTACT-
GACCA and CTCATCACCTTCTGGAATGCA; Mmp3 was ampliﬁed with
GTTCCTGATGTTGGTGGCTT and AGCCTTGGCTGAGTGGTAGA as for-
ward and reverse primers, respectively. As a control for total RNA,
qPCR for 18 S rRNA was performed with the forward and reverse
primers TCGGAACTGAGGCCATGATT and CCTCCGACTTTCGTTCTT-
GATT. Real-time PCR was performed using LightCycler System
(Roche Diagnostics, Indianapolis, IN) according to the manufacturer's
instructions. Fast Start DNA Master SYBR Green I (Roche Diagnostics,
Indianapolis, IN) was used in the PCR reaction. PCR data were
analyzed with LightCycler Software ver.3 (Roche Diagnostics, India-
napolis, IN) and S100A4 and Mmp3 expressions were quantiﬁed
relative to the signals representing 18 SrRNA expression.
Immunocytochemical detection of E-cadherin
Immunoﬂuorescent analysis was performed as described in Fata
et al. (2007). In brief, Eph4 cells were allowed to cluster on ultra low
adhesion plates for 24 h as described above. Approximately 200
clusters were collected by gentle spinning, and washed once in PBS,
and resuspended in 100 μl PBS. 20 μl of this was gently smeared on a
polylysine coated glass slide. Smeared clusters were allowed to dry at
ambient temperature for 15 min and then ﬁxed in paraformaldehyde
for 10 min at ambient temperature. After ﬁxation, slides were air-
dried at ambient temperature for 30 min, followed by blocking in 10%
goat serum in PBS for 1 h at ambient temperature. The primary
antibody, rat anti-E-cadherin (DECMA-1, Abcam), was incubated in
blocking buffer overnight at 4°C, followed by 3×15 min wash in 0.5%
Triton-X in PBS. For detection of primary antibodies, appropriateﬂuorophore-labeled secondary antibodies were used and confocal
images were captured using a Zeiss LSM510 Meta, and Zeiss LSM and
ImageJ (NIH) software.
Western blotting
Culture medium conditioned by 3D collagen cultures for 3 days
was processed for immunoblotting, by mixing 15 μl of conditioned
mediumwithWestern blotting sample buffer and separated on 4–20%
SDS-polyacrylamid gels (Invitrogen). Western blotting was per-
formed as described previously (Pedersen et al., 2004). Anti-MMP-3
rabbit monoclonal antibody (Abcam, Cambridge, MA) was diluted
1:1000 in 5% FBS in PBS, anti-S100A4 rabbit polyclonal antibody
(DAKO, Copenhagen, Denmark) was diluted 1:500 in 5% FBS in PBS,
and ﬁlters incubated overnight at 4°C.
shRNA and expression constructs
The lentivirus for silencing S100A4 was prepared using three
different Mission shRNAi constructs (Sigma-Aldrich, St. Louis, MO)
with the following sequence: sh 1, CCGGCATGATGTGCAAT-
GAATTCTTCTCGAGAAGAATTCATTGCACATCATGTTTTT; sh 2,
CCGGTGTGTCCACCTTCCACAAATACTCGAGTATTTGTGGAAGGTGGA-
CACATTTTT; and sh3, CCGGGATGAGCAACTTGGACAGCAACTC-
GAGTTGCTGTCCAAGTTGCTCATCTTTTT. Stable, constitutively
expressing, S100A4 shRNAi-EpH4 cell lines, were generated using a
ViraPower T-REx lentiviral expression system according to the
manufacturer's protocol (Invitrogen Carlsbad, CA). Brieﬂy, lentivirus
with the shRNA inserts was produced by transfecting the 293FT
producer cell line with the expression construct. EpH4 cells were
infected with the viral supernatants, and stably transduced cells were
selected using the appropriate antibiotic. To prepare expression
plasmids for human S100A4, the ORF was generated using the
following forward and reverse primers: ATGGCGTGCCCTCTGGAGAAG
and TCATTTCTTCCTGGGCTGCT and the product was cloned via the
pGem-T easy vector system (Promega, Madison, WI) and further
introduced into the lentiviral expression vector pLenti CMV/TO Neo
DEST #2 puro (Invitrogen). The construct was veriﬁed by sequencing.
Results
Expression of S100A4 in normal breast
Formalin-ﬁxed, parafﬁn-embedded normal human breast tissue
was analyzed by immunohistochemistry, and positive S100A4
staining was detected in most, but not all ﬁbroblasts in the breast
tissue (Fig. 1A, B and C) All endothelial cells of small vessels were
strongly positive (Fig. 1D). We detected strong positive staining also
in big rounded cells, sometimes with granulated nuclei, presumed to
be breast tissue leucocytes (Fig. 1C, D, E and F). Interestingly, we did
not detect positive staining in the luminal epithelial cells of the ducts
or lobules.We did not detect any staining in adipocytes. To investigate
whether the expression of S100A4 in mammary gland changes during
the different stages of development (ductal elongation in virgin
animals, pregnancy, lactation and involution), total RNA isolated from
the 4th inguinal mammary gland from mice at each developmental
stage was subjected to real-time reverse transcriptase PCR (qPCR).
The data demonstrated the highest level of S100A4 mRNA in the
mammary gland during ductal elongation (Richert et al., 2000)
(Fig. 1J). Interestingly, the lowest levels of S100A4 mRNA were
observed during lactation, indicating that the protein has no major
biological function in the lactation process consistent with the fact
that during lactation, differentiated milk producing epithelial cells of
the alveoli ﬁll most of the mammary gland and the stromal
compartment is subdued (Richert et al., 2000). S100A4 mRNA levels
is, however, reestablished in the involuting mammary gland,
Fig. 1. Expression of S100A4 in normal mammary gland. Representative brightﬁeld images of formalin-ﬁxed parafﬁn-embedded normal human breast tissue sections (Abcam)
analyzed by immunohistochemistry for expression of S100A4 protein, using an in-house monoclonal antibody (22.3, (Flatmark et al., 2004). (A) Positive staining in occasional cells
adjacent to luminal epithelial cells, possibly tissue leucocytes (red arrows). (A, B and C) Positive staining was detected in most but not all ﬁbroblasts in the breast tissue, (black
arrows pointing upwards, A and C positive staining, B negative staining). (D) All the endothelial cells of small vessels were strongly positive. (C, D, E, F) Throughout the breast tissue,
we detected strong positive staining in big, rounded cells, sometimes granulated, assumingly breast tissue leucocytes (black arrows pointing down). (G–I) Control without primary
antibody. (J) Expression of S100A4 in normal mouse mammary gland development. qPCR using total RNA isolated from the 4th inguinal mammary gland from CD1 mice of each
developmental stage and mouse S100A4 primers. The amount of S00A4 mRNA was normalized to 18 S RNA. *= signiﬁcantly lower level S100A4 mRNA as measured by two tailed
Student's t-test. Error bars are SEM. Mammary glands from at least two animals in each developmental stage.
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and involuting mice.
Effects of extracellular S100A4 on branching morphogenesis in mouse
primary organoids
The striking modulation of S100A4 prompted a more detailed
examination of its role in the developing mammary gland. To easily
manipulate the phenotype and to explore the mechanism, we utilized
a 3D organotypic assay of branching morphogenesis developed in our
laboratory (Fata et al., 2007). In brief, mammary gland organoids were
isolated from the 4th inguinal mammary gland of 10- to 14-week-old
mice and grown embedded in Matrigel. The branching process was
induced after 24 h through addition of TGFα, a cytokine prominently
expressed in the mammary gland in vivo (Snedeker et al., 1991).
Addition of recombinant mouse S100A4 protein by itself did not
induce branching (data not shown). However, when added together
with TGFα, it altered the branching phenotype by increasing the
number of resulting buds (Fig. 2A and B, and Supplementary Fig. 1).
The presence of S100A4 in the primary cultures did not, however,
change the overall percentage of branching organoids or the length of
the branching tubules (results not shown). Since non-branching
organoids were unaffected, and S100A4 did not induce branchingalone, we hypothesized that S100A4 stimulated a process already
ongoing in the branching organoids.
Previously, MMP-3 was shown to be involved in branching
morphogenesis in transgenic animals and in culture (Fata et al.,
2007; Lochter et al., 1997a; Simian et al., 2001). In order to unravel
factors contributing to the increased branching in the S100A4-treated
cultures, qPCRwas performed. S100A4 treatment in combinationwith
TGFα induced a 15-fold increase in MMP-3 expression compared to
control (Fig. 2C), correspondingwith an increased secretion of MMP-3
to the culture medium (Fig. 2D). Adding S100A4 alone gave only a
weak induction of MMP-3, indicating a synergy between S100A4 and
TGFα effects. RNA and medium from the primary organoid cultures
was also tested for S100A4-mediated effects on MMP-14, -9 and -2
(results not shown). MMP-3 was the only MMP found to respond
signiﬁcantly to topical addition of S100A4.
Effects of S100A4 on branching morphogenesis in normal mouse
mammary epithelial cells
The primary cultures of mouse organoids are highly enriched for
epithelial cells. However, the cultures also contained remaining fractions
of mammary gland stromal cells. In order to study the direct effect of
S100A4 on mammary gland epithelial cells, and the mechanisms by
Fig. 2. Effects of extracellular S100A4 on branching morphogenesis in primary mouse mammary gland organoids grown in 3D Matrigel cultures. (A) Brightﬁeld images of
representative organoids, 96 h after addition of 4 μg/ml S100A4 in combination with TGFα, to the culture medium, compared to TGFα alone. (B) Quantiﬁcation of branching
morphogenesis after treatment of the organoids with S100A4 protein in combination with TGFα. The frequency plots illustrate number of buds on the ten largest organoids in each
well. Mean number of buds was signiﬁcantly higher in S100A4 treated compared to control wells (15.1 vs. 11.6) (Pb0.01). (C) S100A4 induced Mmp3 mRNA expression from
primary mammary gland organoids. qPCR with mouse Mmp3 primers on total RNA from primary mammary gland organoid cultures treated with 4 μg/ml recombinant S100A4
protein for 96 h, compared to pro-GRP as control protein (a protein of same size, with the same his tag, and produced in the same manner as the recombinant S100A4 protein,
Pb0.04) and vehicle control (PBS). (D) A representative Western gel of medium from primary organoid cultures, stained with anti MMP-3 antibody. The ponceau staining is shown
as a loading control. 15 μl from three parallel wells from one experiment was loaded on the gel.
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process, we employed a deﬁned assay system of normal mouse
mammary epithelial cells. Preformed clusters of EpH4 cells (Reichmann
et al., 1989)will, growand formbranchingduct-like structures,whenput
in 3Dcollagen cultures and stimulatedwith growth factors such as TGFα,
in a process resembling ductal branching (Nelson et al., 2006; Simian et
al., 2001).When grown in 2D cultures on tissue culture plastic, the EpH4
cell line had endogenous expression of S100A4. In order to avoid
unwanted effects of the endogenous protein, stable anti-S100A4 shRNA
transduced variants (anti-S100A4 shRNAi cells, sh 1, sh 2, and sh3), and a
scrambled sh variant (sh scr) as control, were made (Supplementary
Fig. 2). To further verify S100A4-speciﬁc effects, human S100A4 was
reintroduced in the anti-S100A4 sh1 knockdown cell line (sh1/huA4) by
a lentiviral delivered expression construct (Supplementary Fig. 2).
Preformed clusters from these cell lines were put in 3D collagen gels.
Interestingly, in this branching assay, using TGFα as stimulant, the
control cell line transduced with the scrambled control shRNA branched
verywell, 57%of the clusters had twoormorebranches compared to only
15% in the sh1 cell line (Pb0.045) (Fig. 3A and B). Furthermore, wewere
able to restore the branching phenotype by reintroducing S100A4expression, or by adding recombinant S100A4 protein to the cultures
(Fig. 3A and B). These results demonstrated that S100A4, in combination
with TGFα, had a direct effect on the epithelial cells, increasing the
branching phenotype. Furthermore, the effect was independent of the
extracellular matrix composition.
Branching morphogenesis is a complicated and well-regulated
process, depending on proliferation, motility and proteolysis (Fata
et al., 2007; Nelson et al., 2006; Simian et al., 2001). The cell lines were
therefore assayed for differences in proliferation, morphology
(Supplementary Fig. 2), and motility (scratch assay, results not
shown), and we detected no signiﬁcant differences when grown in 2D
cultures on tissue culture plastic, or in 3D without growth factor
addition (results not shown).
S100A4 induced MMP-3 expression in normal mammary epithelial cell
lines
In mouse primary organoid cultures, recombinant S100A4 induced
MMP-3 expression, and probably, thereby enhanced the branching
phenotype. A similar phenotypic effect of S100A4 was observed in the
Fig. 3. S100A4 induces branching morphogenesis of clustered mammary epithelial cells grown in 3D collagen cultures. Preclustered EpH4 clones were seeded into 3 mg/ml collagen
gels and allowed to branch. (A) Representative images of clusters from shRNA transduced EpH4 cells cultured in 3 mg/ml collagen for 72 h. (B). Quantiﬁcation of the percentage of
branching clusters in the 3D collagen cultures in A. All clusters in a well having more than two branches were counted and downregulation of S100A4 was found to signiﬁcantly
reduce the EpH4 cells ability to undergo branching morphogenesis (Pb0.045, sh scr compared to sh1.).
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the transduced EpH4 cell lines, qPCR and immunoblotting of the
conditioned cell culture medium were performed. Our results showed
that both endogenously expressed (Fig. 4A), and the extracellular form
of S100A4 (Fig. 4B), indeed inducedMMP-3 expression in all the shRNA
transduced EpH4 cells, while the human S100A4 transduced cell line
(sh1/huA4), expressing high levels of S100A4 and MMP-3, did not
respond to additional extracellular S100A4.Western blot of conditioned
medium from the 3D collagen cultures demonstrated a corresponding
increase inMMP-3 secretion (Fig. 4C showing the S100A4 shRNA clones
sh2 and sh3 and 5D showing clone sh1). The induction of MMP-3
corresponded well to the observed increase of branching (Fig. 3B),
indicating that the two events were connected.
It has previously been shown that TGFα-mediated induction of
MMP-3 was dependent on signaling through mitogen-activated
protein kinase (MEK) in mouse primary mammary organoids (Fata
et al., 2007). Furthermore, extracellular S100A4 has been shown to
induce Erk phosphorylation (Klingelhofer et al., 2009). It was
therefore of interest to examine whether S100A4-mediated induction
of MMP-3 was MEK-dependent, and the MEK inhibitor PD98059 was
added to 3D collagen cultures of clustered sh1 cells (Fig. 5A and B).
As expected, themRNA (not shown) and protein data (Fig. 5D, lane
1 compared to lane 3) conﬁrmed dependency on MEK for growth
factor induced MMP-3 expression. Presence of the MEK inhibitor also
totally abolished the clusters ability to form branches (Fig. 5A) when
stimulated with both TGFα and S100A4. Consistent with this, in the
presence of MEK inhibitor, S100A4 was not able to induce MMP-3
mRNA expression (Fig. 5C). Interestingly, this result did not
correspond to the protein data since extracellular MMP-3 was
increased by addition of S100A4 also in the presence of PD98059
(Fig. 5D). It is therefore surprising that presence of the MEK inhibitor
totally abolished the clusters ability to form branches (Fig. 5A) when
stimulated with both TGFα and S100A4. It is, however, well known
that inhibiting MEK also inhibits cell proliferation, and this might
explain why the clusters were not able to make branches, even in the
presence of extracellular MMP-3 (Fig. 5A and D, lane 2).These data
indicate that MEK signaling is involved in S100A4-mediated MMP-3
induction, but the discrepancy between the mRNA and protein datamight also suggest that S100A4 triggered other MEK independent
posttranscriptional MMP-3 regulatory pathways.
S100A4 modulated cell–cell adhesion in normal mammary epithelial cell
lines
When grown as suspension cultures in low adhesion tissue culture
wells for preclustering, the anti-S100A4 sh cell lines presented a
phenotypic change compared to the sh scr control cell line and the EpH4
mother cell line. The control cells formed round, tight clusters with
smooth edges, while sh1, sh2 and sh3 formed irregular clusters where
the cell–cell contact seem to be modulated (Fig. 6A), implying that
downregulation of endogenous S100A4 expression had effects on cell–
cell adhesion when cells were grown in suspension. Interestingly, the
sh1/huA4 cell line where S100A4 is reintroduced displayed a partially
restored phenotype, forming both tight round clusters, and irregular
clusters when grown in low adhesion plates. The presence of different
phenotypes might be explained by variable transduction efﬁciency
resulting in heterogeneous expression of human S100A4 in this cell line.
S100 dimers have been suggested to act as bridging factors,
bringing their binding partners together (Zimmer et al., 2003). In light
of this, we tested whether addition of extracellular S100A4 to the
suspension cultures where able to revert the adhesion phenotype but
could not detect any effect on the intracellular adhesion in the clusters
(results not shown). Seemingly, the downregulation of S100A4 gene
expression did not just mechanically alter the strength of the
extracellular cell–cell adhesion forces but had a more profound effect
on the function of the cell–cell adhesion molecules.
The expression of S100A4 has previously been linked to loss of E-
cadherin (Andersen et al., 2004; Keirsebilck et al., 1998; Kohya et al.,
2003; Moriyama-Kita et al., 2005), and clusters from the different sh
transduced EpH4 cell lines were therefore subjected to immuno-
ﬂuorecence staining with anti-E-cadherin antibodies. This revealed an
alteration of E-cadherin distribution in the anti-S100A4 shRNA cell
lines (Fig. 6B), where E-cadherin demonstrated a more punctuated,
vesicular, pattern of distribution, which was reverted when endog-
enous expression of S100A4 was restored. The vesicular staining,
visible in the cytoplasm from the cell membrane to the perinuclear
Fig. 4. S100A4 induces MMP-3 expression in mammary epithelial cells grown in 3D collagen cultures. (A) Effect of endogenously expressed S100A4 and (B) effect of extracellular
S100A4 (12 μg/ml) on Mmp3 expression in 3D cultures treated with TGFα, as measured by qPCR. The sh1/huA4 cell line expressed signiﬁcantly higher amounts of Mmp3 mRNA
compared to sh scr and sh1 cells, while the sh scr and sh1 cells responded to topical addition of recombinant S100A4 by a signiﬁcant increase in Mmp3 mRNA. C) Western blot of
conditioned medium from 3D collagen cultures of control and two different shRNA transduced cell lines treated with or without 12 μg/ml recombinant S100A4 in combination with
TGFα. The immunoblot was labeled with anti MMP-3 antibody. Ponceau staining was used as loading control.
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lular distribution of the E-cadherin molecules. Membranous E-
cadherin expression was partially restored in the sh1/huA4 cell line,
verifying that the change in E-cadherin distribution was caused by
modulation of endogenous S100A4 expression.
Discussion
The link between expression of S100A4 in breast carcinoma cells,
and poor patient outcome, has been soundly established (Ismail et al.,
2008; Lee et al., 2004; Rudland et al., 2000). Since very few studies have
looked at the expression and function of this protein in non-malignant
cells and tissue, the aim for the present work was to elucidate the
biological function of S100A4 in normal mammary gland. The
expression of S100A4 in mammary gland and during mammary gland
development was investigated using immunohistochemistry and qPCR,
respectively. For investigation of the biological role of S100A4 in
mammary gland branching morphogenesis, we employed two model
systems: a physiologically relevant, laminin-rich 3D assay with primary
cells (Fata et al., 2007), and EpH4 cells, a non-tumorigenic and
functionally normal mouse mammary epithelial cell line, cultivated in
type I collagen (Reichmann et al., 1989). In both cell systems, it wasrevealed that S100A4, in concert with TGFα, positively regulated
mammary gland branching phenotype and caused induction of MMP-
3 expression. Additionally, in clusters of EpH4 cells, S100A4 caused
modulation of intracellular E-cadherin distribution.
Using a highly speciﬁc anti-human S100A4 antibody (Flatmark et al.,
2004), positive stainingprimarily in the stromal compartmentof normal
human breast tissue was detected. This is in concordance with previous
reports using different antibodies (Cabezon et al., 2007; Pedersen et al.,
2002; Rudland et al., 2000), altogether conﬁrming the impression of
S100A4 as mainly expressed in the stroma. Since the anatomy of the
human and mouse mammary glands differ, we also looked at S100A4
immunostaining in normal mouse mammary gland, with similar
outcome (Supplementary Fig. 3). Expression of S100A4 in early stage
breast carcinoma cells has been reported as an independent marker of
poor prognosis (Ismail et al., 2008; Lee et al., 2004; Rudland et al., 2000).
In light of this, our results are particularly interesting, implying that
during malignant transformation of mammary epithelial cells, S100A4
expression increases, giving the S100A4 expressing carcinoma cells an
advantage in the metastatic process.
Mammary gland is dynamic, undergoing development and stromal
rearrangements throughout life. By examining the expression of
S100A4 in mouse mammary glands from different developmental
Fig. 5. S100A4 induced branching was dependent of MEK activity. (A) Brightﬁeld images of representative sh1 cell clusters in 3D collagen cultures with or without 12 μg/ml S100A4,
and/or the 25 μM of the MEK inhibitor PD98059 (Cell Signaling Technology, Inc. Danvers, MA) in combination with TGFα. Magniﬁcation is 10×. (B) Quantiﬁcation of the percentage
of branching clusters in 3D collagen cultures of sh1 cells treated as indicated in graph. (C) qPCR using Mmp3 primers on total RNA isolated from cultures in B. The induction of Mmp3
mRNA was signiﬁcantly lower in the presence of the MEK inhibitor, (1.4-fold vs. 4.3-fold in the control, '=Pb0.05). (D) Representative Western blot of conditioned medium from
cultures in B, labeled with anti MMP-3 antibody. Ponceau was used as loading control.
Fig. 6. S100A4 affects cell–cell adhesion molecules. Left side: brightﬁeld images of clustered mammary epithelial cells (EpH4 cells), in suspension cultures. The EpH4 cells were
transduced with S100A4 shRNA (sh1) and scrambeld shRNA (sh scr) as control. The bottom panel is sh1 cells overexpressing human S100A4 (sh1/huA4). Right side: confocal images
of clusters stained with an anti-E-cadherin antibody (green), visualizing intracellular distribution of E-cadherin. The nuclei are counterstained with DAPI (blue).
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whereas S100A4 expression was obliterated during lactation, mean-
ing that the calcium binding protein is unnecessary for normal
function of the terminally differentiated alveolar epithelial cells.
During lactation the amount of stroma is greatly decreased (Richert
et al., 2000), our ﬁnding therefore agrees with the concept of S100A4
as a stromal protein, participating in processes where the stroma
undergoes rearrangements. To test this hypothesis, a physiologically
relevant organotypic branching morphogenesis assay (Fata et al.,
2007) was utilized, and indeed, the results demonstrated that S100A4
positively regulated the branching phenotype of primary organoids
embedded in Matrigel. In light of the results discussed above and
numerous previous studies where S100A4 induces cell motility,
proteolytic activity, and/or invasion in various cell types (Ambartsu-
mian et al., 2001; Saleem et al., 2006; Schmidt-Hansen et al., 2004;
Semov et al., 2005; Takenaga and Kozlova, 2006; Tarabykina et al.,
2007; Zou et al., 2005), this ﬁnding may explain how S100A4
signiﬁcantly contributes to the aggressiveness of mammary carcino-
ma cells. The obtained results show that S100A4 induces an invasive
and proteolytic phenotype in normal mammary epithelial cells.
During malignant transformation, the neoplastic epithelial cells
respond to the increased presence of S100A4, as they are programmed
to, consequently promoting their own aggressive behavior.
Primary mammary organoids are heterogenous and contain ﬁbro-
blasts in addition to luminal and myoepithelial cells, making it difﬁcult
to determine the individual cell type's response to factors added into the
microenvironment. To further unravel the direct extracellular and
endogenous effects of S100A4 onmammary epithelial cells in a deﬁned
cellular environment, preclustered EpH4 cells undergoing TGFα
induced branching morphogenesis in 3D type I collagen gels was
employed. Endogenous S100A4 expression in the EpH4 cells was
minimized using S100A4 shRNA constructs. A lentiviral-delivered
expression vector containing human S100A4 was utilized to revert the
knockdown phenotype and to compare the biological effects of the
endogenous and extracellularly added protein. Our results demonstrat-
ed that independent of the matrix composition, the biological effect of
the extracellular and the endogenously expressed protein was the
same; S100A4 had a direct effect on the mammary epithelial cells,
inducing MMP-3 expression, and increased the branching phenotype.
Interestingly, silencing of S100A4 in the EpH4 cells reduced the
branching, but not the amount of MMP-3 mRNA. It is likely that by
removal of S100A4, the cells became less responsive to TGFα stimuli,
while the background level of MMP-3 mRNA was not affected. When
S100A4 was reintroduced, by endogenous expression, or by recombi-
nant protein, the cells responded to the combination of TGFα and
S100A4, by differentiation toward a more invasive phenotype with
higher expression of proteolytic enzymes, and hence more inclined to
undergo growth factor induced branching.
MMP-3 has previously been shown to induce branching
morphogenesis in mouse mammary organoids, and furthermore,
MMP activity was indispensable for growth factor induced mam-
mary gland branching morphogenesis (Simian et al., 2001). It was
therefore not possible to remove MMP-3 from our assay, to directly
verify the link between S100A4, MMP-3 induction, and branching.
We did, however, see the same association between induction of
MMP-3 and S100A4 re-expression/addition of recombinant S100A4,
in all anti-S100A4 shRNA clones, ruling out the possibility that this
effect was caused by clonal selection. Overexpression of MMP-3 in
mammary gland has previously been shown to increase in vivo
branching and cause increased incidence of preneoplastic lesions
and invasive breast tumors compared to control mice (Sympson
et al., 1995). It was later shown that MMP-3 also induced epithelial–
mesenchymal transition (EMT) and malignant transformation in
cultured cells (Lochter et al., 1997a; Lochter et al., 1997b; Lochter
et al., 1999; Sternlicht et al., 1999). Altogether, it has been clearly
demonstrated that deregulation of MMP-3 is a deleterious eventnormal breast tissue. This study signiﬁes that S100A4 can act as an
MMP-3 inducer, highlighting the signiﬁcance of S100A4 deregula-
tion in early stage breast cancer.
It was previously established that signaling through MEK was
essential for MMP-3 expression in the primary organoid model system
(Fata et al., 2007). By means of a MEK inhibitor, we revealed that this
was the case, also in cultures of clustered EpH4 cells. When inhibiting
MEK, the growth factor induced expression ofMMP-3was subdued, and
the clusters did not display a branching phenotype. Interestingly, the
MEK inhibitor completely blocked the S100A4 induced expression of
MMP-3mRNA,while the inhibitory effect of the protein expressionwas
much weaker. The exact molecular mechanism by which S100A4 exert
its signaling is still incompletely understood, and both NF-κB activation,
and the MAP kinase pathways have been suggested as modulators of
S100A4 signaling (Boye et al., 2008).Ourdata strengthen thehypothesis
that MEK signaling is involved in S100A4-mediated MMP-3 induction
during mammary gland development, but the observed discrepancy
between the mRNA and protein data might also suggest that S100A4
triggered other MEK-independent posttranscriptional pathways. Alto-
gether, our data showed that S100A4 and TGFα had synergistic effects
on expression of MMP-3 supporting the hypothesis that S100A4 is a
natural participant in the cascade of events controlling the invasive
process of branching morphogenesis.
When preclustering the S100A4 shRNA cell lines, we observed a
phenotypical change in cell–cell adhesion, combined with an alteration
of E-cadherin distribution. In the sh scr control cell line, E-cadherin was
concentrated to cell–cell borders, with even intensity, while the anti-
S100A4 shRNA cell lines (sh1, sh2 and sh3) demonstrated a more
disperse, vesicular expression in the cytoplasm, suggestive of ongoing
redistribution of E-cadherin in these clusters (de Beco et al., 2009). E-
cadherin and S100A4 expression have, in several cell systems, been
shown to be inversely regulated (Keirsebilck et al., 1998; Kohya et al.,
2003; Moriyama-Kita et al., 2005). In mouse mammary tumor cells,
S100A4-mediated downregulation of E-cadherin favored disruption of
cell–cell adhesion and subsequent stimulation of invasive behavior
(Keirsebilck et al., 1998).
Interestingly, S100A4, MMP-3 and E-cadherin have all been
associated with the onset of EMT. Transfection of murine proximal
tubular epithelial cells with S100A4 gave a more elongated, ﬁbroblast-
like phenotype, and induced expression of mesenchymal markers.
Moreover, cytokine-induced EMT was accompanied by de novo
expression of S100A4, and when S100A4 induction was blocked, the
renal epithelial cells were not able to undergo EMT (Okada et al., 1997).
In light of these results, it is likely that overexpression or addition of
S100A4 to mammary epithelial cells induces a more mesenchymal-like
phenotypewith altered cell–cell adhesion,more proteolytic activity and
hence more prone to form branches.
In summary, we have shown that in normal mammary gland,
S100A4 is a stromal factor contributing positively to branching
morphogenesis through induction ofMMP-3 expression and E-cadherin
modulation.We propose that S100A4 is one of themediators in a tightly
controlled mammary gland developmental program, driving epithelial
cells towards a more invasive phenotype during branching morpho-
genesis. As a consequence, when this program is deregulated and
exploited by the metastatic carcinoma cells, S100A4 becomes an
important factor in early stage breast cancer. Our work underlines the
importance of S100A4, proposes this protein as a target for anti-
metastatic therapy, and calls for further elucidation of the molecular
function and regulation of S100A4 in mammary gland development.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.ydbio.2010.12.033.
Acknowledgments
The authors wish to thank Jamie Inman for providing mouse
mammary gland tissue sections. The work from MJB's laboratory is
190 K. Andersen et al. / Developmental Biology 352 (2011) 181–190supported by grants from the U.S. Department of Energy, Ofﬁce of
Biological and Environmental Research and Low Dose Radiation Program
(contract no. DE-AC02-05CH1123); by National Cancer Institute (awards
R37CA064786, U54CA126552, R01CA057621, U54CA112970,
U01CA143233, and NCI U54CA143836-Bay Area Physical Sciences–
Oncology Center, University of California, Berkeley, California); and by
U.S. Department of Defense (W81XWH0810736). The work was
furthermore supported by the Norwegian Cancer Society (grant no A-
05121 to KA and PR-2006-0272 to GMM), the National Program for
Research on Functional Genomics (#158954/S10) and the Program for
Centers for Research-based Innovation (#174938) of the Norwegian
Research Council (toG.M.M.), and the Jeanette and SørenBothners Legacy
(to G.M.M.).
References
Ambartsumian, N.S., Grigorian, M.S., Larsen, I.F., Karlstrom, O., Sidenius, N., Rygaard, J.,
Georgiev, G., Lukanidin, E., 1996. Metastasis of mammary carcinomas in GRS/A
hybrid mice transgenic for the mts1 gene. Oncogene 13, 1621–1630.
Ambartsumian, N., Klingelhofer, J., Grigorian, M., Christensen, C., Kriajevska, M.,
Tulchinsky, E., Georgiev, G., Berezin, V., Bock, E., Rygaard, J., Cao, R., Cao, Y.,
Lukanidin, E., 2001. The metastasis-associated Mts1(S100A4) protein could act as
an angiogenic factor. Oncogene 20, 4685–4695.
Andersen, K., Nesland, J.M., Holm, R., Florenes, V.A., Fodstad, O., Maelandsmo, G.M.,
2004. Expression of S100A4 combined with reduced E-cadherin expression
predicts patient outcome in malignant melanoma. Mod. Pathol. 17, 990–997.
Barraclough, R., Savin, J., Dube, S.K., Rudland, P.S., 1987. Molecular cloning and sequence
of the gene for p9Ka. A cultured myoepithelial cell protein with strong homology to
S-100, a calcium-binding protein. J. Mol. Biol. 198, 13–20.
Boye, K., Grotterod, I., Aasheim, H.C., Hovig, E., Maelandsmo, G.M., 2008. Activation of
NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms
and identiﬁcation of target genes. Int. J. Cancer 123, 1301–1310.
Cabezon, T., Celis, J.E., Skibshoj, I., Klingelhofer, J., Grigorian, M., Gromov, P., Rank, F.,
Myklebust, J.H., Maelandsmo, G.M., Lukanidin, E., Ambartsumian, N., 2007.
Expression of S100A4 by a variety of cell types present in the tumor
microenvironment of human breast cancer. Int. J. Cancer 121, 1433–1444.
Davies, B.R., Barraclough, R., Davies, M.P., Rudland, P.S., 1993. Production of themetastatic
phenotype by DNA transfection in a rat mammary model. Cell Biol. Int. 17, 871–879.
Davies, M.P., Rudland, P.S., Robertson, L., Parry, E.W., Jolicoeur, P., Barraclough, R., 1996.
Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic
mice induces metastasis of mammary tumours. Oncogene 13, 1631–1637.
deBeco, S., Gueudry, C., Amblard, F., Coscoy, S., 2009. Endocytosis is required for E-cadherin
redistribution atmature adherens junctions. Proc. Natl Acad. Sci. USA106, 7010–7015.
Donato, R., 2003. Intracellular and extracellular roles of S100 proteins. Microsc. Res.
Tech. 60, 540–551.
Fata, J.E., Werb, Z., Bissell, M.J., 2004. Regulation of mammary gland branching
morphogenesis by the extracellular matrix and its remodeling enzymes. Breast Cancer
Res. 6, 1–11.
Fata, J.E.,Mori, H., Ewald, A.J., Zhang, H., Yao, E.,Werb, Z., Bissell,M.J., 2007. TheMAPK(ERK-
1, 2) pathway integrates distinct and antagonistic signals from TGFalpha and FGF7 in
morphogenesis of mouse mammary epithelium. Dev. Biol. 306, 193–207.
Flatmark, K., Pedersen, K.B., Nesland, J.M., Rasmussen, H., Aamodt, G., Mikalsen, S.O.,
Bjornland, K., Fodstad, O., Maelandsmo, G.M., 2003. Nuclear localization of the
metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer.
J. Pathol. 200, 589–595.
Flatmark, K., Maelandsmo, G.M., Mikalsen, S.O., Nustad, K., Varaas, T., Rasmussen, H.,
Meling, G.I., Fodstad, O., Paus, E., 2004. Immunoﬂuorometric assay for themetastasis-
related protein S100A4: release of S100A4 from normal blood cells prohibits the use
of S100A4 as a tumor marker in plasma and serum. Tumour Biol. 25, 31–40.
Garrett, S.C., Varney, K.M., Weber, D.J., Bresnick, A.R., 2006. S100A4, a mediator of
metastasis. J. Biol. Chem. 281, 677–680.
Gongoll, S., Peters, G., Mengel, M., Piso, P., Klempnauer, J., Kreipe, H., von Wasielewski,
R., 2002. Prognostic signiﬁcance of calcium-binding protein S100A4 in colorectal
cancer. Gastroenterology 123, 1478–1484.
Grigorian, M., Tulchinsky, E., Burrone, O., Tarabykina, S., Georgiev, G., Lukanidin, E.,
1994. Modulation of mts1 expression in mouse and human normal and tumor cells.
Electrophoresis 15, 463–468.
Gupta, P.B., Onder, T.T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R.A., Lander, E.S.,
2009. Identiﬁcation of selective inhibitors of cancer stem cells by high-throughput
screening. Cell 138, 645–659.
Hirai, Y., Lochter, A., Galosy, S., Koshida, S., Niwa, S., Bissell, M.J., 1998. Epimorphin functions
as a key morphoregulator for mammary epithelial cells. J. Cell Biol. 140, 159–169.
Ismail, N.I., Kaur, G., Hashim, H., Hassan, M.S., 2008. S100A4 overexpression proves to be
independent marker for breast cancer progression. Cancer cell international 8, 12.
Keirsebilck, A., Bonne, S., Bruyneel, E., Vermassen, P., Lukanidin, E., Mareel, M., van Roy,
F., 1998. E-cadherin andmetastasin (mts-1/S100A4) expression levels are inversely
regulated in two tumor cell families. Cancer Res. 58, 4587–4591.
Klingelhofer, J., Moller, H.D., Sumer, E.U., Berg, C.H., Poulsen, M., Kiryushko, D., Soroka,
V., Ambartsumian, N., Grigorian, M., Lukanidin, E.M., 2009. Epidermal growth factor
receptor ligands as new extracellular targets for the metastasis-promoting S100A4
protein. FEBS J. 276, 5936–5948.Kohya, N., Kitajima, Y., Jiao, W., Miyazaki, K., 2003. Effects of E-cadherin transfection on
gene expression of a gallbladder carcinoma cell line: repression of MTS1/S100A4
gene expression. Int. J. Cancer 104, 44–53.
Lee, W.Y., Su, W.C., Lin, P.W., Guo, H.R., Chang, T.W., Chen, H.H., 2004. Expression of
S100A4 and Met: potential predictors for metastasis and survival in early-stage
breast cancer. Oncology 66, 429–438.
Lochter, A., Galosy, S., Muschler, J., Freedman, N., Werb, Z., Bissell, M.J., 1997a. Matrix
metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that
leads to stable epithelial-to-mesenchymal conversion and a premalignant
phenotype in mammary epithelial cells. J. Cell Biol. 139, 1861–1872.
Lochter, A., Srebrow, A., Sympson, C.J., Terracio, N., Werb, Z., Bissell, M.J., 1997b.
Misregulation of stromelysin-1 expression in mouse mammary tumor cells
accompanies acquisition of stromelysin-1-dependent invasive properties. J. Biol.
Chem. 272, 5007–5015.
Lochter, A., Werb, Z., Bissell, M.J., 1999. Transcriptional regulation of stromelysin-1 gene
expression is altered during progression of mouse mammary epithelial cells from
functionally normal to malignant. Matrix Biol. 18, 455–467.
Maelandsmo, G.M., Hovig, E., Skrede, M., Engebraaten, O., Florenes, V.A., Myklebost, O.,
Grigorian, M., Lukanidin, E., Scanlon, K.J., Fodstad, O., 1996. Reversal of the in vivo
metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme.
Cancer Res. 56, 5490–5498.
Matsumoto, K., Irie, A., Satoh, T., Ishii, J., Iwabuchi, K., Iwamura, M., Egawa, S., Baba, S.,
2007. Expression of S100A2 and S100A4 predicts for disease progression and
patient survival in bladder cancer. Urology 70, 602–607.
Moriyama-Kita, M., Endo, Y., Yonemura, Y., Heizmann, C.W., Miyamori, H., Sato, H.,
Yamamoto, E., Sasaki, T., 2005. S100A4 regulates E-cadherin expression in oral
squamous cell carcinoma. Cancer Lett. 230, 211–218.
Nelson, C.M., Vanduijn, M.M., Inman, J.L., Fletcher, D.A., Bissell, M.J., 2006. Tissue
geometry determines sites of mammary branching morphogenesis in organotypic
cultures. Sci. NY N. Y 314, 298–300.
Okada, H., Danoff, T.M., Kalluri, R., Neilson, E.G., 1997. Early role of Fsp1 in epithelial-
mesenchymal transformation. Am. J. Physiol. 273, F563–F574.
Pedersen, K.B., Nesland, J.M., Fodstad, O., Maelandsmo, G.M., 2002. Expression of S100A4, E-
cadherin, alpha- andbeta-catenin in breast cancer biopsies. Br. J. Cancer 87, 1281–1286.
Pedersen, K.B., Andersen, K., Fodstad, O., Maelandsmo, G.M., 2004. Sensitization of
interferon-gamma induced apoptosis in human osteosarcoma cells by extracellular
S100A4. BMC Cancer 4, 52.
Reichmann, E., Ball, R., Groner, B., Friis, R.R., 1989. New mammary epithelial and
ﬁbroblastic cell clones in coculture form structures competent to differentiate
functionally. J. Cell Biol. 108, 1127–1138.
Richert, M.M., Schwertfeger, K.L., Ryder, J.W., Anderson, S.M., 2000. An atlas of mouse
mammary gland development. J. Mammary Gland Biol. Neoplasia 5, 227–241.
Rudland, P.S., Platt-Higgins, A., Renshaw, C., West, C.R., Winstanley, J.H., Robertson, L.,
Barraclough, R., 2000. Prognostic signiﬁcance of the metastasis-inducing protein
S100A4 (p9Ka) in human breast cancer. Cancer Res. 60, 1595–1603.
Saleem, M., Kweon, M.H., Johnson, J.J., Adhami, V.M., Elcheva, I., Khan, N., Bin Hafeez, B.,
Bhat, K.M., Sarfaraz, S., Reagan-Shaw, S., Spiegelman, V.S., Setaluri, V., Mukhtar, H.,
2006. S100A4 accelerates tumorigenesis and invasion of human prostate cancer
through the transcriptional regulation of matrix metalloproteinase 9. Proc. Natl
Acad. Sci. USA 103, 14825–14830.
Schmidt-Hansen, B., Ornas, D., Grigorian, M., Klingelhofer, J., Tulchinsky, E., Lukanidin,
E., Ambartsumian, N., 2004. Extracellular S100A4(mts1) stimulates invasive
growth of mouse endothelial cells and modulates MMP-13 matrix metalloprotein-
ase activity. Oncogene 23, 5487–5495.
Semov, A., Moreno, M.J., Onichtchenko, A., Abulrob, A., Ball, M., Ekiel, I., Pietrzynski, G.,
Stanimirovic, D., Alakhov, V., 2005. Metastasis-associated protein S100A4 induces
angiogenesis through interaction with Annexin II and accelerated plasmin
formation. J. Biol. Chem. 280, 20833–20841.
Simian, M., Hirai, Y., Navre, M., Werb, Z., Lochter, A., Bissell, M.J., 2001. The interplay of
matrix metalloproteinases, morphogens and growth factors is necessary for
branching of mammary epithelial cells. Dev. Camb. Engl. 128, 3117–3131.
Snedeker, S.M., Brown, C.F., DiAugustine, R.P., 1991. Expression and functional
properties of transforming growth factor alpha and epidermal growth factor
during mouse mammary gland ductal morphogenesis. Proc. Natl Acad. Sci. USA 88,
276–280.
Sternlicht, M.D., Lochter, A., Sympson, C.J., Huey, B., Rougier, J.P., Gray, J.W., Pinkel, D.,
Bissell, M.J., Werb, Z., 1999. The stromal proteinase MMP3/stromelysin-1 promotes
mammary carcinogenesis. Cell 98, 137–146.
Sternlicht, M.D., Kouros-Mehr, H., Lu, P., Werb, Z., 2006. Hormonal and local control of
mammary branching morphogenesis. Differ. research biological diversity 74,
365–381.
Strutz, F., Okada, H., Lo, C.W., Danoff, T., Carone, R.L., Tomaszewski, J.E., Neilson, E.G.,
1995. Identiﬁcation and characterization of a ﬁbroblast marker: FSP1. J. Cell Biol.
130, 393–405.
Sympson, C.J., Bissell, M.J., Werb, Z., 1995. Mammary gland tumor formation in
transgenic mice overexpressing stromelysin-1. Semin. Cancer Biol. 6, 159–163.
Takenaga, K., Kozlova, E.N., 2006. Role of intracellular S100A4 for migration of rat
astrocytes. Glia 53, 313–321.
Tarabykina, S., Grifﬁths, T.R., Tulchinsky, E., Mellon, J.K., Bronstein, I.B., Kriajevska, M.,
2007. Metastasis-associated protein S100A4: spotlight on its role in cell migration.
Curr. Cancer Drug Targets 7, 217–228.
Zimmer, D.B., Wright Sadosky, P., Weber, D.J., 2003. Molecular mechanisms of S100-
target protein interactions. Microsc. Res. Tech. 60, 552–559.
Zou, M., Al-Baradie, R.S., Al-Hindi, H., Farid, N.R., Shi, Y., 2005. S100A4 (Mts1) gene
overexpression is associated with invasion and metastasis of papillary thyroid
carcinoma. Br. J. Cancer 93, 1277–1284.
